Selected article for: "control study and multicenter study"
Author: Mert, Ali; Vahaboğlu, Haluk; Arslan, Ferhat; Batirel, Ayşe; Saraçoğlu, Kemal Tolga; Bastug, Aliye; Çağatay, Atahan; Irmak, İlim; Dizman, Gülçin Telli; Ertenli, İhsan; Altunal, Lütfiye Nilsun; Sengel, Buket Ertürk; Bayram, Mehmet; Omma, Ahmet; Amikishiyev, Shirkhan; Aypak, Adalet; Bes, Cemal; Bolukçu, Sibel; Içten, Sacit; Topeli, Arzu; Bektaş, Murat; Arslan, Birsen Yiğit; Öztürk, Sinan; Çomoğlu, Şenol; Aydin, Selda; Küçükşahin, Orhan; Içaçan, Ozan Cemal; Ince, Burak; Aghamuradov, Sarvan; Mutlu, Melek Yalçin; Şimşek, Funda; Emre, Salih; Ustun, Cemal; Ergen, Pinar; Aydin, Özlem; Koç, Meliha Meriç; Sevindik, Ömür Gökmen; Odabaşı, Zekaver; Korten, Volkan; Bodur, Hurrem; Güner, Rahmet; Ünal, Serhat; Kocak, Mehmet; Gül, Ahmet
Title: Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls
  • Cord-id: k00nyz1k
  • Document date: 2021_9_13
    • ID: k00nyz1k
    Snippet: Coronavirus disease-2019 (COVID-19) associated pneumonia may progress into acute respiratory distress syndrome (ARDS). Some patients develop features of macrophage activation syndrome (MAS). Elevated levels of IL-6 were reported to be associated with severe disease, and anti-IL-6R tocilizumab has been shown to be effective in some patients. This retrospective multicenter case–control study aimed to evaluate the efficacy of tocilizumab in hospitalized COVID-19 patients, who received standard of
    Document: Coronavirus disease-2019 (COVID-19) associated pneumonia may progress into acute respiratory distress syndrome (ARDS). Some patients develop features of macrophage activation syndrome (MAS). Elevated levels of IL-6 were reported to be associated with severe disease, and anti-IL-6R tocilizumab has been shown to be effective in some patients. This retrospective multicenter case–control study aimed to evaluate the efficacy of tocilizumab in hospitalized COVID-19 patients, who received standard of care with or without tocilizumab. Primary outcome was the progression to intubation or death. PSMATCH (SAS) procedure was used to achieve exact propensity score (PS) matching. Data from 1289 patients were collected, and study population was reduced to 1073 based on inclusion–exclusion criteria. The composite outcome was observed more frequently in tocilizumab-users, but there was a significant imbalance between arms in all critical parameters. Primary analyses were carried out in 348 patients (174 in each arm) after exact PS matching according to gender, ferritin, and procalcitonin. Logistic regression models revealed that tocilizumab significantly reduced the intubation or death (OR 0.40, p = 0.0017). When intubation is considered alone, tocilizumab-users had > 60% reduction in odds of intubation. Multiple imputation approach, which increased the size of the matched patients up to 506, provided no significant difference between arms despite a similar trend for intubation alone group. Analysis of this retrospective cohort showed more frequent intubation or death in tocilizumab-users, but PS-matched analyses revealed significant results for supporting tocilizumab use overall in a subset of patients matched according to gender, ferritin and procalcitonin levels. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00296-021-04965-6.

    Search related documents:
    Co phrase search for related documents
    • achieve auc and logistic regression model: 1
    • achieve balance and logistic regression: 1
    • activity block and macrophage activation: 1
    • activity block and macrophage activation syndrome: 1
    • acute ards respiratory distress syndrome and administration day: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and loading dose: 1
    • acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute ards respiratory distress syndrome and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute ards respiratory distress syndrome and lopinavir mg day twice ritonavir: 1
    • acute ards respiratory distress syndrome and lung infiltrate: 1
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute ards respiratory distress syndrome and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome progress and macrophage activation: 1, 2
    • acute ards respiratory distress syndrome progress and macrophage activation syndrome: 1, 2
    • acute hepatic injury and logistic regression: 1, 2, 3, 4
    • acute hepatic injury and logistic regression analysis: 1